| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J |
NCT00946985: 28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years |
|
|
| Terminated | 4 | 163 | US, Canada, Europe, RoW | paliperidone palmitate, oral risperidone | Ortho-McNeil Janssen Scientific Affairs, LLC | Schizophrenia | 03/10 | 03/10 | | |
NCT01211704: Paliperidone Palmitate Efficacy and Safety in Bipolar Disorder Complicated by Alcoholism |
|
|
| Withdrawn | 4 | 0 | US | Paliperidone Palmitate, INVEGA® SUSTENNA™, Placebo | University of Miami, Ortho-McNeil, Inc. | Bipolar Disorder | 12/11 | 02/12 | | |
NCT01193166: Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital |
|
|
| Withdrawn | 4 | 0 | US | paliperidone palmitate, risperidone, olanzapine, aripiprazole, haloperidole, quetiapine, perphenazine, paliperidone | Ortho-McNeil Janssen Scientific Affairs, LLC | Schizophrenia | 09/12 | 09/12 | | |
| Completed | 4 | 311 | US | haloperidol decanoate, Haldol, paliperidone palmitate, Invega Sustenna | New York State Psychiatric Institute, National Institute of Mental Health (NIMH), Duke University, University of North Carolina, Chapel Hill | Schizophrenia, Schizoaffective Disorder | 07/13 | 07/16 | | |
NCT01682161: A Comparative Study to Evaluate the Evolution of Medication Satisfaction and Adherence in Patients Unsatisfied With Current Oral Atypical Antipsychotics by Switching Medication to Paliperidone Palmitate |
|
|
| Completed | 4 | 154 | RoW | Paliperidone palmitate, INVEGA SUSTENNA | Janssen Korea, Ltd., Korea | Schizophrenia | 09/13 | 09/13 | | |
NCT01157351: 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated |
|
|
| Completed | 4 | 450 | US | paliperidone, risperidone, haloperidole, perphenazine, aripiprazole, quetiapine, paliperidone palmitate, olanzapine | Janssen Scientific Affairs, LLC | Schizophrenia | 12/13 | 12/13 | | |
NCT01527305: A Study to Evaluate the Effectiveness and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia |
|
|
| Completed | 4 | 212 | RoW | Paliperidone palmitate, Sustenna | Johnson & Johnson Pte Ltd | Schizophrenia | 12/13 | 12/13 | | |
NCT01458379: Brain Myelination Effects of Paliperidone Palmitate Versus Oral Risperidone in First Episode Schizophrenia |
|
|
| Not yet recruiting | 4 | 50 | US | Paliperidone Palmitate, Risperidone | University of California, Los Angeles, Ortho-McNeil Janssen Scientific Affairs, LLC | Schizophrenia | 10/14 | 12/15 | | |
NCT01685931: A Study of Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated by Oral Antipsychotics |
|
|
| Completed | 4 | 617 | RoW | Paliperidone Palmitate | Xian-Janssen Pharmaceutical Ltd. | Schizophrenia | 12/14 | 12/14 | | |
NCT01860781: The Effect of Paliperidone Palmitate in Schizophrenia |
|
|
| Completed | 4 | 30 | RoW | paliperidone palmitate, paliperidone palmitate(sustenna) | Seoul National University Hospital | Schizophrenia | 12/15 | 12/15 | | |
NCT02472652: Aripiprazole, Abilify Maintena Collaborative Clinical Protocol |
|
|
| Terminated | 4 | 2 | US | Abilify Maintena, Aripiprazole | Gazda, Thomas D., M.D., PC, Otsuka America Pharmaceutical | Sexual Dysfunction | 12/16 | 03/17 | | |
ACTRN12618001113246: Effectiveness of long-acting paliperidone palmitate (PP1M) compared with oral antipsychotics on satisfaction, subjective well-being and service engagement in subjects with non-acute but symptomatic schizophrenia. |
|
|
| Completed | 4 | 70 | | | Department of Neuroscience, University of Turin, Department of Neuroscience, University of Turin | schizophrenia | | | | |
NCT03080194: The Effect of a Community-based LAI-treated Management Model on the Violence Risk of Patients With Schizophrenia |
|
|
| Unknown status | 4 | 150 | NA | paliperidone palmitate, Sustenna, control group | Maosheng Fang | Schizophrenia | 04/18 | 04/18 | | |
NCT03713658: A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities |
|
|
| Completed | 4 | 34 | RoW | Risperidone 3 mg, Paliperidone Palmitate 50 mg eq., R092670, Paliperidone Palmitate 75 mg eq., Paliperidone Palmitate 100 mg eq., Paliperidone Palmitate 150 mg eq., Paliperidone Palmitate 175 mg eq., Paliperidone Palmitate 263 mg eq., Paliperidone Palmitate 350 mg eq., Paliperidone Palmitate 525 mg eq. | Janssen Research & Development, LLC | Schizophrenia | 12/19 | 12/19 | | |
| Completed | 4 | 536 | Europe, RoW | Aripiprazole, Abilify, Aripiprazole depot, Abilify maintena, Paliperidone, Invega, Paliperidone palmitate, Xeplion | UMC Utrecht | Schizophrenia | 08/20 | 08/20 | | |
NCT01451736: Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia |
|
|
| Completed | 4 | 146 | US | paliperidone palmitate, Invega Sustenna, risperidone, Risperdal | University of California, Los Angeles, National Institute of Mental Health (NIMH), Janssen Scientific Affairs, LLC | Schizophrenia (Recent-onset) | 12/21 | 12/21 | | |
2022-001582-12: Open, multicenter, randomized clinical trial to evaluate the efficacy and safety of aripiprazole vs paliperidone / risperidone using multi-omics data in patients with a first psychotic episode. Ensayo clínico abierto, multicéntrico, aleatorizado para evaluar la eficacia y seguridad de aripiprazol vs paliperidona / risperidona mediante datos multi-ómicos en pacientes con un primer episodio psicótico. |
|
|
| Ongoing | 4 | 244 | Europe | Injection, Abilify Maintena, Xeplion | Consorcio Centro de Investigacion Biomedica en Red (CIBER), Instituto de Salud Carlos III | First episode SZ-spectrum individuals Pacientes con un primer episodio psicótico, First episode SZ-spectrum individuals Pacientes con un primer episodio psicótico, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
CASPAR, NCT04940039: A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings |
|
|
| Completed | 4 | 93 | RoW | Risperidone 3 mg, Paliperidone Palmitate 50 mg eq., R092670, Paliperidone Palmitate 75 mg eq., Paliperidone Palmitate 100 mg eq., Paliperidone Palmitate 150 mg eq., Paliperidone Palmitate 175 mg eq., Paliperidone Palmitate 263 mg eq., Paliperidone Palmitate 350 mg eq., Paliperidone Palmitate 525 mg eq. | Janssen-Cilag International NV | Schizophrenia | 04/24 | 04/24 | | |
